Literature DB >> 17115325

The prognostic impact of successful cardioversion of atrial fibrillation in patients with organic heart disease.

T Kleemann1, T Becker, K Dönges, M Vater, B Gut, S Schneider, J Senges, K Seidl.   

Abstract

The aim of the study was to evaluate the prognostic impact of successful cardioversion (CV) compared to failed CV in patients with atrial fibrillation (AF) and organic heart disease. A total of 471 consecutive patients with organic heart disease from the prospective single center anticoagulation registry ANTIK who underwent CV of AF or atrial flutter were analyzed. 417 patients (89%) could be successfully cardioverted. In 54 patients (11%) CV failed, these patients remained in AF. After 5 years there were 92 (24%) deaths among patients with restored sinus rhythm at index admission and 20 (38%) deaths among those who remained in AF after CV (unadjusted OR 1.9, 95% CI 1.1-3.6). After adjustment for age, gender and ejection fraction, successful CV was not associated with a beneficial effect on mortality (OR 0.72, 95% CI 0.43-1.21). Thus, successful CV is not an independent predictor of mortality on multivariate analysis. However, it remains a marker for a better prognosis in patients with organic heart disease as these patients have a lower unadjusted longterm mortality.

Entities:  

Mesh:

Year:  2006        PMID: 17115325     DOI: 10.1007/s00392-006-0466-8

Source DB:  PubMed          Journal:  Clin Res Cardiol        ISSN: 1861-0684            Impact factor:   5.460


  25 in total

1.  A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation.

Authors:  Isabelle C Van Gelder; Vincent E Hagens; Hans A Bosker; J Herre Kingma; Otto Kamp; Tsjerk Kingma; Salah A Said; Julius I Darmanata; Alphons J M Timmermans; Jan G P Tijssen; Harry J G M Crijns
Journal:  N Engl J Med       Date:  2002-12-05       Impact factor: 91.245

2.  Electrical remodeling of the atria following loss of atrioventricular synchrony: a long-term study in humans.

Authors:  P B Sparks; H G Mond; J K Vohra; S Jayaprakash; J M Kalman
Journal:  Circulation       Date:  1999-11-02       Impact factor: 29.690

3.  Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program.

Authors:  Lars G Olsson; Karl Swedberg; Anique Ducharme; Christopher B Granger; Eric L Michelson; John J V McMurray; Margareta Puu; Salim Yusuf; Marc A Pfeffer
Journal:  J Am Coll Cardiol       Date:  2006-04-27       Impact factor: 24.094

4.  ACE-inhibitor treatment attenuates atrial structural remodeling in patients with lone chronic atrial fibrillation.

Authors:  A Boldt; A Scholl; J Garbade; M E Resetar; F W Mohr; J F Gummert; St Dhein
Journal:  Basic Res Cardiol       Date:  2005-12-29       Impact factor: 17.165

Review 5.  Female preponderance in ibutilide-induced torsade de pointes.

Authors:  Ramesh M Gowda; Ijaz A Khan; Gopikrishna Punukollu; Balendu C Vasavada; Terrence J Sacchi; Sabrina L Wilbur
Journal:  Int J Cardiol       Date:  2004-06       Impact factor: 4.164

6.  Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study.

Authors:  Scott D Corley; Andrew E Epstein; John P DiMarco; Michael J Domanski; Nancy Geller; H Leon Greene; Richard A Josephson; Joyce C Kellen; Richard C Klein; Andrew D Krahn; Mary Mickel; L Brent Mitchell; Joy Dalquist Nelson; Yves Rosenberg; Eleanor Schron; Lynn Shemanski; Albert L Waldo; D George Wyse
Journal:  Circulation       Date:  2004-03-08       Impact factor: 29.690

7.  Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin.

Authors:  Brian F Gage; Carl van Walraven; Lesly Pearce; Robert G Hart; Peter J Koudstaal; B S P Boode; Palle Petersen
Journal:  Circulation       Date:  2004-10-11       Impact factor: 29.690

8.  Analysis of cause-specific mortality in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study.

Authors:  Jonathan S Steinberg; Ara Sadaniantz; Jack Kron; Andrew Krahn; D Marty Denny; James Daubert; W Barton Campbell; Edward Havranek; Katherine Murray; Brian Olshansky; Gearoid O'Neill; Magdi Sami; Stanley Schmidt; Randle Storm; Miguel Zabalgoitia; John Miller; Mary Chandler; Elaine M Nasco; H Leon Greene
Journal:  Circulation       Date:  2004-03-29       Impact factor: 29.690

9.  Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials. Studies of Left Ventricular Dysfunction.

Authors:  D L Dries; D V Exner; B J Gersh; M J Domanski; M A Waclawiw; L W Stevenson
Journal:  J Am Coll Cardiol       Date:  1998-09       Impact factor: 24.094

10.  The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study.

Authors:  A D Krahn; J Manfreda; R B Tate; F A Mathewson; T E Cuddy
Journal:  Am J Med       Date:  1995-05       Impact factor: 4.965

View more
  6 in total

1.  Quality of life and occurrence of atrial fibrillation in long-term follow-up of common type atrial flutter ablation: ablation with irrigated 5 mm tip and conventional 8 mm tip electrodes.

Authors:  Axel Meissner; Martin Christ; Petra Maagh; Rolf Borchard; Marc van Bracht; Ingo Wickenbrock; Hans-Joachim Trappe; Gunnar Plehn
Journal:  Clin Res Cardiol       Date:  2007-08-31       Impact factor: 5.460

2.  Flecainide for cardioversion in patients at elevated cardiovascular risk and persistent atrial fibrillation: a prospective observational study.

Authors:  Fikret Er; Orhan Aslan; Evren Caglayan; Natig Gassanov; Amir M Nia; Erland Erdmann; Stephan Rosenkranz
Journal:  Clin Res Cardiol       Date:  2010-02-24       Impact factor: 5.460

3.  Atrial tachycardias following circumferential pulmonary vein ablation: observations during catheter ablation.

Authors:  Marc Horlitz; Philipp Schley; Dong-In Shin; Beatrice Tonnellier; Hartmut Gülker
Journal:  Clin Res Cardiol       Date:  2007-11-28       Impact factor: 5.460

4.  AFFECT: a prospective, open-label, multicenter trial to evaluate the feasibility and safety of a short-term treatment with subcutaneous certoparin in patients with persistent non-valvular atrial fibrillation.

Authors:  Ulrich Tebbe; Ralph Oeckinghaus; Karl-Friedrich Appel; Hubertus Heuer; Hendrik Haake; Egbert Eggers; Karlheinz Seidel; Jan Adams; Job Harenberg
Journal:  Clin Res Cardiol       Date:  2008-03-05       Impact factor: 5.460

5.  Long-term prognosis after cardioversion of the first episode of symptomatic atrial fibrillation: a condition believed to be benign revised.

Authors:  Torsten Becker; Thomas Kleemann; Margit Strauss; Klaus Doenges; Steffen Schneider; Jochen Senges; Karlheinz Seidl
Journal:  Clin Res Cardiol       Date:  2007-10-19       Impact factor: 5.460

6.  Dynamic Electrocardiography is Useful in the Diagnosis of Persistent Atrial Fibrillation Accompanied with Second-Degree Atrioventricular Block.

Authors:  Lei Zhang; Junling He; Miaojun Lian; Li Zhao; Xudong Xie
Journal:  Acta Cardiol Sin       Date:  2018-09       Impact factor: 2.672

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.